肝素
抗凝剂
抗血栓
抗凝血酶
药理学
医学
混凝级联
抗凝药
凝血酶
免疫学
内科学
血小板
作者
John Hogwood,Barbara Mulloy,R. Lever,Elaine Gray,Clive P. Page
出处
期刊:Pharmacological Reviews
[American Society for Pharmacology and Experimental Therapeutics]
日期:2023-02-15
卷期号:75 (2): 328-379
被引量:51
标识
DOI:10.1124/pharmrev.122.000684
摘要
Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100 years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence, which potentiates the inhibitory action of antithrombin, a major inhibitor of the coagulation cascade. More recently it has been elucidated that heparin exhibits anti-inflammatory effect via interference of the formation of neutrophil extracellular traps and this may also contribute to heparin9s antithrombotic activity. This illustrates that heparin interacts with a broad range of biomolecules, exerting both anticoagulant and nonanticoagulant actions. Since our previous review, there has been an increased interest in these nonanticoagulant effects of heparin, with the beneficial role in patients infected with SARS2-coronavirus a highly topical example. This article provides an update on our previous review with more recent developments and observations made for these novel uses of heparin and an overview of the development status of heparin-based drugs.
Significance Statement
This state-of-the-art review covers recent developments in the use of heparin and heparin-like materials as anticoagulant, now including immunothrombosis observations, and as nonanticoagulant including a role in the treatment of SARS-coronavirus and inflammatory conditions.
科研通智能强力驱动
Strongly Powered by AbleSci AI